Amlodipine for Myocardial Iron in Thalassemia

Thalassemia Clinical Trial

— AMIT  

Official title:

Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02065492
• Other study ID #: AMIT
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: February 17, 2014
• Last updated: June 28, 2017
• Start date: February 2014
• Est. completion date: November 2015

Study information

• Verified date: June 2017
• Source: Aga Khan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Children with thalassemia may have high iron levels after receiving blood transfusions. These high iron levels can have damaging effects on the body, especially the heart. Conventionally only chelation therapy was given for prevention of iron buildup in the heart. However, current research has shown that another drug, amlodipine, also helps to slow down the deposition of iron in the heart. This study is designed to see if patients receiving amlodipine along with their regular chelation therapy have a slower rate of iron buildup in the heart when compared with patients who are receiving chelation only.

Description:

Null Hypothesis There is no difference between the efficacy of chelation plus amlodipine therapy and chelation therapy alone in retarding the rate of myocardial iron deposition in thalassemia patients with iron overload and a constant transfusion need.

Alternate Hypothesis Chelation plus amlodipine therapy is more efficacious than chelation therapy alone in retarding the rate of myocardial iron deposition in thalassemia patients with iron overload and a constant transfusion need.

The aim of the investigators study is to determine if amlodipine, an L-type specific calcium channel blocker, in addition to the standard aggressive chelation therapy, can retard the deposition of iron in the myocardium of thalassemia patients with significant myocardial iron load with or without cardiomyopathy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 20 Years

Eligibility

Inclusion Criteria:

• Pediatric patients aged = 6 and = 20 years managed at AKUH for at least 1 year

• = 10 blood transfusion in life time

• Transfusion need = 180 ml/kg/year

• Serum ferritin = 1000 ug/dl

• Patient deemed capable of receiving chelation therapy (by treating hematologist) either subcutaneous infusion of Deferoxamine (Desferal) (3-5 days a week) or oral deferasirox (daily) or Defeperione (oral) or a combination of Desferal and Defeperione.

• Patients who have been on a stable chelation regimen = 6 months

• Completed and signed Informed consent/assent.

Exclusion Criteria:

• Patients with known hypersensitivity to amlodipine.

• Patients with known sinoatrial nodal disease or aortic stenosis.

• Patients with known severe myocardial dysfunction, defined as A LV ejection fraction of = 4 SD for age even without symptoms.

• Patients with known signs and symptoms of heart failure.

• Patients with a T2* value of < 4 ms on cardiac MRI.

• Patients with systolic blood pressures = 2 SD for age (systemic hypotension) at the time of enrolment.

• Patients with previously diagnosed significant congenital heart diseases or acquired heart diseases other than thalassemia (as defined earlier).

• Patients with known contraindications to MRI (pacemakers, cerebral aneurysm metal clips, etc.)

• Patient with a known history of developing tetany after use of a calcium channel blocker

• Known pregnancy.

Related Conditions & MeSH terms

• Thalassemia

Intervention

Drug:
• Standard Chelation
This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
• Amlodipine
doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial

Locations

Country	Name	City	State
Pakistan	Aga Khan University Hospital	Karachi	Sindh

Sponsors (1)

Lead Sponsor	Collaborator
Aga Khan University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of amlodipine in retarding rate of myocardial iron deposition (Assessed by change in T2* times)	Each patient will be randomized into either of two study arms: amlodipine plus chelation or chelation alone. All patients will undergo MRI and T2* imaging at baseline and then at 6 and 12 month follow-up visits. Efficacy of Amlodipine will be assessed using change in T2* times.	At baseline, and then at 6 months and 12 months from the start of the study
Secondary	Effect of amlodipine therapy on left ventricular size, systolic and diastolic function	Cardiac MRI and echocardiogram will be utilized to assess both systolic and diastolic function. Basic parameters such as left ventricular end diastolic volume, left ventricular systolic volume and the ejection fraction will be measured.; Mitral Inflow Doppler as well as Tissue Doppler Imaging will be used to assess diastolic dysfunction.; Conventional Pulsed Doppler Echocardiography will be utilized to derive the myocardial performance index (Tei Index) of each patient which will serve as a surrogate for systolic function.; Peak global and segmental longitudinal left and right ventricular strain and strain rate will be calculated using speckle tracking by tracing images obtained from the apical 4-chamber view. Peak global and segmental right and left ventricular circumferential strain and strain rate will also be calculated from a parasternal, mid-cavity short axis view using speckle tracking also.	At baseline and then at 6 months and 12 months from the start of the study
Secondary	Efficacy of amlodipine in retarding liver iron content (mg/g)	Liver iron content will be measured using T2* imaging of the liver	At baseline and then at 6 months and 12 months from the start of the study
Secondary	Adverse effects of amlodipine therapy	Data on adverse effects will be be collected using the adverse event form. The adverse effects anticipated include fatigue, nausea, edema, palpitations, flushing, headache, dizziness, blurred vision, somnolence, cough, hypertension and sinus bradycardia. Any other adverse event will also be reported. Adverse events that require only symptomatic management will be treated by the participant's primary hematologist. Adverse events that require hospitalization will also be managed by the participant's primary hematologist and the costs incurred will be covered by the research fund. Cardiovascular adverse events that require outpatient or inpatient management will be treated by the Principal Investigator and his cardiology team and all costs incurred will be covered by the research fund.	At baseline and at 6 months and 12 months from the start of the study; at all visits to the Clinical Trial Unit pharmacy at the Aga Khan Hosptal for dispensing amlodipine and at all routine visits to the outpatient hematology clinic